Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy

The addition of immune checkpoint inhibitors (ICIs) to the therapeutic armamentarium for solid malignancies has resulted in unprecedented improvements in patient outcomes in many cancers. The landscape of ICIs continues to evolve with novel approaches such as dual immune checkpoint blockade and comb...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Selina K. Wong, Caroline A. Nebhan, Douglas B. Johnson
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
age
Acceso en línea:https://doaj.org/article/07c9e054d32446cb97d320077b60b483
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!